Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

(2010) Walter M. Stadler et al.   CANCER

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

(2010) E. S. Robinson et al.   Clinical Journal of the American Society of Nephrology

Targeted therapy in renal cell carcinoma

(2010) Bhanu K Vakkalanka et al.   CURRENT OPINION IN UROLOGY

Patient adherence and persistence with oral anticancer treatment

(2009) K. Ruddy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α

(2009) Robert A. Figlin et al.   CANCER

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer

(2009) Joaquim Bellmunt et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and Efficacy of Sorafenib Therapy in Patients With Metastatic Kidney Cancer With Impaired Renal Function

(2009) Venkata Parsa et al.   Clinical Genitourinary Cancer

EORTC-GU group expert opinion on metastatic renal cell cancer

(2009) Theo M. de Reijke et al.   EUROPEAN JOURNAL OF CANCER

Observation Should be Considered as an Alternative in Management of Renal Masses in Older and Comorbid Patients

(2009) Christian Beisland et al.   EUROPEAN UROLOGY

In Reply

(2009) Andrew Vickers et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma

(2009) Eric Jonasch et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

(2009) M.P. Sablin et al.   JOURNAL OF UROLOGY

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

(2009) Janice P. Dutcher et al.   MEDICAL ONCOLOGY

Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)

(2009) R. Anderson et al.   ONCOLOGIST

The changing pattern of kidney cancer incidence and mortality in Europe

(2008) Fabio Levi et al.   BJU INTERNATIONAL

The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses

(2008) Steven M. Lucas et al.   CANCER

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

(2008) Arkadiusz Z. Dudek et al.   CANCER

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

(2008) Kiran Gupta et al.   CANCER TREATMENT REVIEWS

The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce

(2008) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork?

(2008) Daniel J. Lenihan   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial

(2008) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

(2008) M. E. Lacouture et al.   ONCOLOGIST

Systemic Therapy for Metastatic Renal Cell Carcinoma

(2008) Glenn S. Kroog et al.   UROLOGIC CLINICS OF NORTH AMERICA

Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma

(2008) Alvin S. Wong et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Vascular complications of selected cancer therapies

(2008) Iyad N Daher et al.   Nature clinical practice. Cardiovascular medicine

There's many a slip twixt cup and lip: adherence issues in cancer therapy

(2008) Lesley Fallowfield   Nature clinical practice. Oncology